Literature DB >> 6738653

Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome.

R S Klein, C A Harris, C B Small, B Moll, M Lesser, G H Friedland.   

Abstract

We studied the frequency with which unexplained oral candidiasis led to unequivocal acquired immunodeficiency syndrome (AIDS) in patients at risk. Twenty-two previously healthy adults with unexplained oral candidiasis, of whom the 19 tested had a reversed T4/T8 ratio and 20 had generalized lymphadenopathy, were compared with 20 similar patients with a reversed T4/T8 ratio and generalized lymphadenopathy who did not have oral candidiasis. All were intravenous-drug abusers, homosexual or bisexual men, or both. Thirteen of the 22 patients with oral candidiasis (59 per cent) acquired a major opportunistic infection or Kaposi's sarcoma at a median of three months (range, 1 to 23) as compared with none of 20 patients with generalized lymphadenopathy and immunodeficiency but without candidiasis who were followed for a median of 12 months (range, 5 to 21) (P less than 0.001). AIDS developed in 12 of 15 patients with candidiasis and T4/T8 ratios less than or equal to 0.51, as compared with none of four with ratios equal to or greater than 0.60 (P less than 0.01). We conclude that in patients at high risk for AIDS, the presence of unexplained oral candidiasis predicts the development of serious opportunistic infections more than 50 per cent of the time. Whether the remainder will have AIDS is not yet known.

Entities:  

Mesh:

Year:  1984        PMID: 6738653     DOI: 10.1056/NEJM198408093110602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  179 in total

Review 1.  The significance of oral health in HIV disease.

Authors:  I L Chapple; J Hamburger
Journal:  Sex Transm Infect       Date:  2000-08       Impact factor: 3.519

2.  Evidence for a unique expression of CD4 on murine vaginal CD4+ cells.

Authors:  F L Wormley; M Scott; W Luo; M Baker; J Chaiban; P L Fidel
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

3.  Primary role for CD4(+) T lymphocytes in recovery from oropharyngeal candidiasis.

Authors:  C S Farah; S Elahi; K Drysdale; G Pang; T Gotjamanos; G J Seymour; R L Clancy; R B Ashman
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

4.  Intestinal lesions associated with disseminated candidiasis in an experimental animal model.

Authors:  K A Andrutis; P J Riggle; C A Kumamoto; S Tzipori
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

5.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

6.  Proteomic analysis of azole resistance in Candida albicans clinical isolates.

Authors:  Massoumeh Z Hooshdaran; Katherine S Barker; George M Hilliard; Harald Kusch; Joachim Morschhäuser; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

7.  Vitreous fluorophotometric recordings in HIV infection.

Authors:  M Cellini; A Baldi
Journal:  Int Ophthalmol       Date:  1991-01       Impact factor: 2.031

8.  CD8 T cells and E-cadherin in host responses against oropharyngeal candidiasis.

Authors:  K Quimby; E A Lilly; M Zacharek; K McNulty; J E Leigh; J E Vazquez; P L Fidel
Journal:  Oral Dis       Date:  2011-09-30       Impact factor: 3.511

Review 9.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  New model of oropharyngeal candidiasis in mice.

Authors:  Y Kamai; M Kubota; Y Kamai; T Hosokawa; T Fukuoka; S G Filler
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.